The polyclonal antibody will detect native and recombinant Human VEGFR-2/KDR in ELISA experiments and on the surface or solubilized from different Human cell types.
Cross-Reactivity (Details)
Species reactivity (tested):Human.
Purification
Protein A Affinity Chromatography
Immunogen
Recombinant Human soluble extracellular domain of KDR protein (D1-7). Remarks: The antibody is identical with the former described antibody r212 (see Lit.)
ELISA: Use at 5-15 μg/mL. Western blotting: Use at 10-20 μg/mL. Immunoprecipitation: Use 1-2 μg/mg protein lysate. Neutralizing experiments: Depending on the conditions and ligand concentration startwith 25-50 μg/mL. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Reconstitution
Restore in sterile water to a concentration of 1.0 mg/mL.
Buffer
PBS, pH 7.4 without preservatives or stabilizers
Preservative
Without preservative
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
The lyophilized antibody, thought stable at room temperature, is best stored desiccated below 0 °C. Reconstituted anti-VEGFR-2/KDR is stable at 2-8 °C for one month or can be stored in working aliquots at -20 °C for more than six months.
VEGF receptor 2 is a member of a receptor tyrosine kinase family whose activation plays an essential role in a large number of biological processes such as embryonic development, wound healing, cell proliferation, migration and differentiation. Like other growth factor receptors, upon ligand binding VEGF receptor 2 dimerises and is autophosphorylated on multiple tyrosine residues. These sites can be involved in the regulation of kinase activity or serve as binding sites for SH2 and phosphotyrosine binding containing signalling proteins. Phosphorylation of Tyrosines 1054 and 1059 in the activation loop is required for activation of VEGF receptor 2 and its intrinsic tyrosine kinase activity. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.Synonyms: FLK1, KDR, Kinase NYK, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, VEGF Receptor 2, VEGFR2, Vascular endothelial growth factor receptor 2